The post Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund appeared first on Omnix Medical.
]]>— Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline
— Funding underlines urgent global need for novel, resistance-proof antimicrobials
JERUSALEM, Israel, October 15, 2025 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, announced today that it raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund. Existing shareholders Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited demonstrated strong confidence in Omnix’s approach by taking part in the round alongside new external investors, including Prevail Partners and OurCrowd.
This financing will enable Omnix to complete Phase II proof-of-concept studies for its lead compound, OMN6. The studies will focus on treating life-threatening infections caused by Gram-negative bacteria, particularly Acinetobacter baumannii, including strains resistant to last-line treatments such as carbapenems and colistin. The funding will also support regulatory activities, manufacturing scale-up, and the advancement of Omnix’s broader pipeline of engineered antimicrobial peptides. With this latest round of funding, Omnix has raised a total of $43 million since its inception in 2015.
Tomer Goldberg, Vice President, Managing Director Harel Technology Investments at Harel Insurance & Finance, said: “The rise of antibiotic-resistant infections is not just a medical crisis – it’s a societal one. At Harel, we are dedicated to supporting innovation and biotech, and we believe that companies like Omnix are essential to ensuring the development of effective treatments that protect lives and promote long-term wellbeing.”
“With the co-leadership of Harel Insurance & Finance and the EIC Fund, and the strong continued support of our existing shareholders, we now have the resources to complete Phase II proof-of-concept studies of OMN6, strengthen our regulatory and manufacturing capabilities, and advance our entire pipeline,” said Dr. Moshik Cohen-Kutner, Chief Executive Officer of Omnix Medical. “We are proud to have both the backing of new investors and the renewed trust of our long-standing shareholders. Together, they reflect the confidence in Omnix’s mission to deliver truly novel anti-infective solutions.”
OMN6 is a first-in-class antimicrobial peptide (AMP) with a novel mechanism of action (MoA) based on destroying bacterial cell membranes. It is therefore not only fast acting and bactericidal, but also effective regardless of bacterial genotype or resistance phenotype. OMN6 has so far shown excellent preclinical and clinical results regarding its efficacy, potency, and safety, but also high stability while maintaining bioactivity. The U.S. FDA has granted the compound Fast-Track and QIDP (Qualified Infectious Disease Product) designation.
The post Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund appeared first on Omnix Medical.
]]>The post STUDY: In Vitro Antimicrobial Activity of OMN51 Against MDR Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis appeared first on Omnix Medical.
]]>Authors: Moshe Heching, Moshe Cohen-Kutner, Haim Ben-Zvi, Liora Slomianksy, Elital Chass Maurice, Noa Nur Maymon, Shira Mandel, Michal Oholy, Rony Moses, Michal Lavon, Katherine Kaufman, Orel Mayost Lev-Ari,Tamar Shachar, Joel Weinberg, Mordechai R. Kramer and Niv Bachnoff.
The post STUDY: In Vitro Antimicrobial Activity of OMN51 Against MDR Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis appeared first on Omnix Medical.
]]>The post Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials appeared first on Omnix Medical.
]]>Among the peptides profiled is OMN6, Omnix Medical’s novel 40‑amino‑acid cyclic derivative of cecropin A, which has shown potent activity against Acinetobacter baumannii, a favorable safety profile in 80 healthy volunteers, and is now advancing to a Phase IIa trial (NCT06087536) in hospital‑ and ventilator‑associated pneumonia.
The article also underscores the need for concrete plans to ensure global access to new agents in regions where resistance to Gram‑negative bacilli is most prevalent.
David L. Paterson (2024) Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials, Expert Opinion on Investigational Drugs, 33:4, 371-387, DOI: 10.1080/13543784.2024.2326028
Link to this article: https://doi.org/10.1080/13543784.2024.2326028
The post Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials appeared first on Omnix Medical.
]]>The post Outstanding Scientific Research Award for Omnix Medical’s novel OMN51 appeared first on Omnix Medical.
]]>The work, which summarizes a one-year study evaluating the in vitro antimicrobial activity of Omnix Medical’s novel antimicrobial peptide, OMN51, against Pseudomonas aeruginosa clinical isolates demonstrated potent and consistent efficacy across both sensitive, resistant and multidrug resistant strains, highlighting OMN51’s potential as a powerful new therapeutic candidate.
The post Outstanding Scientific Research Award for Omnix Medical’s novel OMN51 appeared first on Omnix Medical.
]]>The post Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6 appeared first on Omnix Medical.
]]>Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited review is designated to investigational drugs that treat a serious or life-threatening condition and fill an unmet medical need.
OMN6 is Omnix Medical´s lead compound and a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) fundamentally differs from conventional anti-infectives by physically destroying bacterial cell membranes and allowing a fast and effective onset of action regardless of bacterial genotype or resistance phenotype.
In November 2023, Omnix Medical had been granted an IND for a Phase II trial of OMN6 in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC). Both are life-threatening infections that currently lack fast and effective treatments, most of which fall short due to antimicrobial resistances.
“We are excited that the U.S. FDA has granted fast-track designation for our lead compound OMN6,” said Dr. Moshik Cohen-Kutner, CEO of Omnix Medical. “This allows us to accelerate the development of game-changing anti-infectives that are designed to be fast-acting and effective without triggering antimicrobial resistances. We are looking forward to obtaining Phase II results.”
“The fast-track designation brings us one step closer to saving the lives of patients with life-threatening hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) that do not respond to conventional antibiotics and currently have no further therapeutic options,” added Niv Bachnoff, CSO of Omnix Medical.
###
About Omnix Medical
Omnix Medical was founded in 2015 to address the urgent unmet need for new life-saving anti-infective drugs. Omnix´ proprietary technology eliminates bacteria by mimicking the innate immune system of insects which uses unique molecules to efficiently and selectively kill resistant bacterial strains without toxic effects. This mechanism, which is at the core of Omnix´ technology, kills bacteria upon contact and has successfully evolved over 200 million years. The Company’s lead compound is being developed for the treatment of life-threatening hospital-acquired infections (HIA) and has shown significantly higher potency than currently available treatments. Most importantly, Omnix´ technology prevents the development of new resistances and is thus well positioned to become the first-line-treatment to win the war against AMR.
About OMN6
OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 has been optimized from the original AMP by Omnix Medical´s proprietary technology to exhibit not only remarkable efficacy, potency, and safety, but also high stability while maintaining bioactivity. As a result, Omnix Medical believes that its novel peptides can be considered a new class of antimicrobial drugs. OMN6, the Company’s lead compound, is intended for the treatment of life-threatening infections caused by Gram-negative bacteria such as Acinetobacter baumannii.
The post Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6 appeared first on Omnix Medical.
]]>The post Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6 appeared first on Omnix Medical.
]]>JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6.
The multinational, multicenter trial will assess the safety and pharmacokinetics of OMN6 in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).
Omnix Medical´s lead compound OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on a totally novel principle compared to conventional anti-infectives: the compound destroys bacterial cell membranes, enabling a fast and effective onset of action regardless of bacterial genotype or resistance phenotype.
In a randomized, double-blind, placebo-controlled, single ascending dose Phase I study with over 80 healthy volunteers, OMN6 has demonstrated excellent safety and tolerability at clinically significant dose levels. Moreover, complete clearance of the drug could be shown, allowing for multiple daily infusions as is common with anti-infective treatments.
“We are very pleased that the U.S. FDA has approved our planned Phase II study,” said Dr. Moshik Cohen-Kutner, CEO of Omnix Medical. “As we have seen very encouraging results in our previous Phase I trial, we hope that the Phase II data will confirm these data. This would be a key milestone in the development of a novel class of anti-infectives that are not associated with a development of antimicrobial resistance.”
Dr. Niv Bachnoff, CSO of Omnix Medical, added: “We look forward to initiating this Phase II trial in the coming months. Our goal is to provide a potent alternative to conventional anti-infectives and to save the lives of millions of patients worldwide who no longer respond to currently available antibiotics.”
About Omnix Medical
Omnix Medical was founded in 2015 to address the urgent unmet need for new life-saving anti-infective drugs. Omnix´ proprietary technology eliminates bacteria by mimicking the innate immune system of insects which uses unique molecules to efficiently and selectively kill resistant bacterial strains without toxic effects. This mechanism, which is at the core of Omnix´ technology, kills bacteria upon contact and has successfully evolved over 200 million years. The Company’s lead compound is being developed for the treatment of life-threatening hospital-acquired infections (HIA) and has shown significantly higher potency than currently available treatments. Most importantly, Omnix´ technology prevents the development of new resistances and is thus well positioned to become the first-line-treatment to win the war against AMR.
About OMN6
OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 has been optimized from the original AMP by Omnix Medical´s proprietary technology to exhibit not only remarkable efficacy, potency, and safety, but also high stability while maintaining bioactivity. As a result, Omnix Medical believes that its novel peptides can be considered a new class of antimicrobial drugs. OMN6, the Company’s lead compound, is intended for the treatment of life-threatening infections caused by Gram-negative bacteria such as Acinetobacter baumannii.
Corporate Contacts
Moshik Cohen-Kutner, CEO
+972-50-8698218
Niv Bachnoff, CSO
+972-54-238-6023
[email protected]
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
Related Links
Twitter https://twitter.com/MedicalOmnix
LinkedIn http://linkedin.com/company/omnix-medical
The post Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6 appeared first on Omnix Medical.
]]>The post OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office appeared first on Omnix Medical.
]]>We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection.
Importantly, the Notice of Allowance follows the patent protection previously granted to OMN6 in several other major international markets, including the United States, European Union, China, Australia, and Japan. The repeated validation from patent offices worldwide testifies to the unique, innovative, and significant nature of our work in fighting infectious diseases.
Our dedicated team of scientists has invested countless hours in the development of this peptide, with the goal of delivering a novel, effective, and accessible solution for AMR and for the treatment of infectious diseases globally.
With this Notice of Allowance, the intellectual property for our lead peptide is officially recognized and protected until 2037. This provides our company with the exclusive rights to further develop and commercialize our pioneering antimicrobial peptide. It also ensures that we can continue our vital work to advance this treatment without the fear of any patent infringement.
As we move forward, we remain committed to pushing the boundaries of biotechnology to improve healthcare outcomes worldwide. We will keep you updated as we embark on the next clinical phase of our journey.
Thank you for your continued support and trust in our mission.
The post OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office appeared first on Omnix Medical.
]]>The post Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6 appeared first on Omnix Medical.
]]>JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. All endpoints were met: No severe or serious adverse events (SEs/SAEs) were observed at any dose level in the study while clinically meaningful levels of OMN6 were achieved in the blood and complete clearance of the drug was demonstrated, allowing for multiple daily infusions as is common with anti-infective treatments.
The study, conducted in Groningen, The Netherlands, covered a total of 80 healthy volunteers, including a cohort of elderly patients, and was designed as a randomized, double-blind, placebo-controlled, single ascending dose study. Primary endpoints were safety and tolerability of single ascending i.v. doses of OMN6. The secondary endpoint was to evaluate the pharmacokinetics (PK) of OMN6 in the plasma of healthy young and elderly adult volunteers.
OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 has been optimized from the original AMP by Omnix Medical´s proprietary technology to exhibit not only remarkable efficacy, potency, and safety, but also high stability while maintaining bioactivity. As a result, Omnix Medical believes that its novel peptides can be considered a new class of antimicrobial drugs. OMN6, the Company’s lead compound, is intended for the treatment of life-threatening infections caused by Gram-negative bacteria such as Acinetobacter baumannii.
“We are very pleased with these results,” said Dr. Moshik Cohen-Kutner, CEO of Omnix Medical. “They demonstrate that our approach is safe and that the compound is well tolerated at clinically significant doses, even in the elderly. This is a very important milestone as the burden of antimicrobial resistance is estimated to be 4.95 million deaths per year worldwide.”
Dr. Niv Bachnoff, CSO of Omnix Medical, added: “This is a very important milestone on the way to establishing a new class of antibiotics that are orders of magnitude less likely to induce resistance, recrudescence or tolerance in bacterial pathogens. We are now looking forward to preparing a Phase II trial with OMN6 in the coming months.”
###
About Omnix Medical
Omnix Medical was founded in 2015 to address the urgent unmet need for new life-saving anti-infective drugs. Omnix´ proprietary technology eliminates bacteria by mimicking the innate immune system of insects which uses unique molecules to efficiently and selectively kill resistant bacterial strains without toxic effects. This mechanism, which is at the core of Omnix´ technology, kills bacteria upon contact and has successfully evolved over 200 million years. The Company’s lead compound is being developed for the treatment of life-threatening hospital-acquired infections (HIA) and has shown significantly higher potency than currently available treatments. Most importantly, Omnix´ technology prevents the development of new resistances and is thus well positioned to become the first-line-treatment to win the war against AMR.
Corporate Contacts
Moshik Cohen-Kutner, CEO
+972-50-8698218
Niv Bachnoff, CSO
+972-54-238-6023
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
Related Links
http://www.omnixmedical.com/
Twitter https://twitter.com/MedicalOmnix
LinkedIn http://linkedin.com/company/omnix-medical
The post Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6 appeared first on Omnix Medical.
]]>The post RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY appeared first on Omnix Medical.
]]>
We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising awareness for the fight against AMR.
Omnix Medical is a clinical-stage biopharmaceutical company focused on developing innovative anti-infective drugs to combat the growing problem of Antimicrobial Resistance (AMR). Our goal is to offer safer and more effective treatments that are less prone to resistance, to effectively address the threat posed by AMR. We are dedicated to finding a solution to this pressing issue and are confident that our therapies will make a significant impact in the fight against AMR.
The post RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY appeared first on Omnix Medical.
]]>The post OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70 appeared first on Omnix Medical.
]]>Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70.
At Omnix, we are working hard to build our clinical pipeline with new peptide-based drugs that address broad unmet medical needs.
Using Omnix drug discovery platform to screen a wide-ranging array of peptides originating from marine organisms, insects and frogs, we identified these two new peptide families that demonstrate a great potential in targeting hard to treat bacterial pathogens.
Two molecules, OMN51 and OMN71, have been advanced to Lead Optimization and Formulation stages of their development:
OMN51 is a new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa which causes recurrent and persistent infections in patients with Cystic Fibrosis (CF). Cycles of infection and hospitalization promote the development of resistance that significantly reduces treatment solutions.
OMN71 is a new antimicrobial peptide (AMP) targeting bacteria involved with skin infections in patients with Acne or Atopic-Dermatitis. When infections of the skin involve MRSA or P. Acnes high levels of resistance are present and treatment becomes hard and prolonged.
Intensive and comprehensive preclinical research is being conducted at Omnix Medical Laboratories to bring OMN51 and OMN71 to clinical development in parallel with the filing of appropriate patent applications.
The Company’s lead compound, OMN6, is a first-in-class antimicrobial peptide for the treatment of life-threatening hospital acquired infections caused by Gram-negative bacteria. OMN6 has been found to be highly effective on multidrug-resistant Acinetobacter baumannii (AB), especially Carbapenem-resistant AB (CRAB), the #1 priority pathogen according to the WHO/CDC.
Recently, Omnix Medical initiated a Phase I clinical trial testing our lead molecule, OMN6, in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics in healthy subjects. The trial is conducted in Groningen, The Netherlands and results are expected by Q4 2022.
To learn more about the Omnix discovery pipeline, contact us at [email protected].
The post OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70 appeared first on Omnix Medical.
]]>